Cabaletta Bio

Our CEO, Steven Nichtberger, MD Nichtberger, will participate in a fireside chat at the Jefferies London Healthcare Conference today, November 20th. Join the live webcast at 11:30am GMT / 6:30am ET at the following link: https://lnkd.in/eW7A7sWe #jefferies #celltherapy #reset #autoimmune

This morning, Cabaletta Bio announced positive clinical data on CABA-201 demonstrating the potential to achieve compelling clinical responses with all patients discontinuing all immunosuppressants in the first 8 patients dosed across the ongoing Phase 1/2 RESET-Myositis?, RESET-SLE? and RESET-SSc? clinical trials. Read our press release on the News & Media section of our website and join our live investor conference call and webcast today at 8:00a.m. EDT here: https://lnkd.in/eS5EF2gs #celltherapy #myositis #SLE #SSc #reset #autoimmune

Cabaletta Bio is excited to announce that CABA-201 clinical data will be presented in oral and poster presentations at American College of Rheumatology (ACR) Convergence 2024 in November from our RESET clinical development program, evaluating our 4-1BB-containing fully human CD19-CAR T cell investigational therapy. The abstracts are now available here https://lnkd.in/gykfpKbD #reset #ACR24 #celltherapy #autoimmune

Join us for an interactive Innovation Theater at ACR Convergence 2024 on Monday, November 18th at 10:30a ET, featuring David J. Chang, MD, MPH, FACR, our Chief Medical Officer who oversaw the development of the only 2 products approved for systemic lupus erythematosus in the US in over 60 years, and Iain McInnes, Muirhead Professor of Medicine and Versus Arthritis Professor of Rheumatology at the University of Glasgow and a member of our Scientific Advisory Board. We will be discussing emerging clinical & translational data in the field of CAR T cell therapy and an update of the RESET clinical trial program. We look forward to seeing you there! #reset #ACR24 #CART #celltherapy #autoimmune

Today, Cabaletta Bio reported 16 patients enrolled with 10 patients dosed across the RESET? clinical development program as of November 12. There are 40 U.S. clinical sites actively enrolling patients across 5 RESET clinical trials. We are looking forward to presenting clinical data in lupus, myositis, and systemic sclerosis in oral and poster presentations this weekend at ACR Convergence 2024. We also announced that we have expanded clinical development into Europe with EMA CTA authorization for CABA-201 received in lupus and expanded our leadership team with the hires of Gerwin Winter and Nicolette Sherman. Read our Q3 2024 earnings press release here: https://lnkd.in/evmi4RSu #CART #celltherapy #reset #autoimmune

The #CabalettaCrew was honored to participate in the Lupus Foundation of America, Inc.'s 33rd Annual Walk to End Lupus Now in Philadelphia this weekend. We look forward to continuing to support all #LupusWarriors in the fight against this devastating disease. #WalkToEndLupusNow #lupus #autoimmune?

Our CEO, Steven Nichtberger, MD, will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference today, November 11th. Join the live webcast at 10:00am ET at the following link: https://lnkd.in/evMUMVCa #guggenheim #celltherapy #reset #autoimmune

Cabaletta Bio is looking forward to the American College of Rheumatology Convergence 2024 Conference this month in Washington D.C. Join us for an interactive Innovation Theater on Monday, November 18th at 10:30a ET, featuring David J. Chang, MD, MPH, FACR, our Chief Medical Officer who oversaw the development of the only 2 products approved for SLE in the US in over 60 years, and Iain McInnes, Muirhead Professor of Medicine and Versus Arthritis Professor of Rheumatology at the University of Glasgow and a member of our Scientific Advisory Board. We will be discussing emerging clinical & translational data in the field of CAR T cell therapy and an update of the RESET clinical trial program. Look forward to seeing you there! #reset #ACR24 #CART #celltherapy #autoimmune

Cabaletta Bio is excited to be attending today's #LupusABC Meeting on Patient Reported Outcomes in clinical trials! We’re joining leading experts and the #lupus community to chart the best course for integrating patient priorities and needs into the drug evaluation process. More about Lupus ABC: lupusabc.org #LupusVoices #LupusResearch

Cabaletta Bio is excited to announce that CABA-201 clinical data will be presented in oral and poster presentations at American College of Rheumatology (ACR) Convergence 2024 in November from our RESET clinical development program, evaluating our 4-1BB-containing fully human CD19-CAR T cell investigational therapy. The abstracts are now available here https://lnkd.in/gykfpKbD #reset #ACR24 #celltherapy #autoimmune